ATE365748T1 - Polymer-konjugate von neublastin und methoden für deren verwendung - Google Patents

Polymer-konjugate von neublastin und methoden für deren verwendung

Info

Publication number
ATE365748T1
ATE365748T1 AT02714792T AT02714792T ATE365748T1 AT E365748 T1 ATE365748 T1 AT E365748T1 AT 02714792 T AT02714792 T AT 02714792T AT 02714792 T AT02714792 T AT 02714792T AT E365748 T1 ATE365748 T1 AT E365748T1
Authority
AT
Austria
Prior art keywords
neublastin
methods
polymer conjugates
conjugates
polymer
Prior art date
Application number
AT02714792T
Other languages
German (de)
English (en)
Inventor
Dinah Sah
R Pepinsky
Paula Borjack-Sjodin
Stephan Miller
Anthony Rossomando
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of ATE365748T1 publication Critical patent/ATE365748T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
AT02714792T 2001-02-01 2002-01-25 Polymer-konjugate von neublastin und methoden für deren verwendung ATE365748T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26607101P 2001-02-01 2001-02-01

Publications (1)

Publication Number Publication Date
ATE365748T1 true ATE365748T1 (de) 2007-07-15

Family

ID=23013042

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02714792T ATE365748T1 (de) 2001-02-01 2002-01-25 Polymer-konjugate von neublastin und methoden für deren verwendung

Country Status (35)

Country Link
EP (2) EP1862475A1 (enExample)
JP (2) JP4259868B2 (enExample)
KR (2) KR100872807B1 (enExample)
CN (1) CN1500095B (enExample)
AR (1) AR035077A1 (enExample)
AT (1) ATE365748T1 (enExample)
AU (1) AU2002247037B2 (enExample)
BG (1) BG66393B1 (enExample)
BR (1) BR0206852A (enExample)
CA (1) CA2436407C (enExample)
CY (1) CY1106886T1 (enExample)
CZ (1) CZ20032080A3 (enExample)
DE (1) DE60220879T2 (enExample)
DK (1) DK1355936T3 (enExample)
EA (1) EA009771B1 (enExample)
EE (1) EE05537B1 (enExample)
ES (1) ES2289091T3 (enExample)
GE (1) GEP20063916B (enExample)
HU (1) HU228973B1 (enExample)
IL (2) IL156941A0 (enExample)
IS (1) IS2867B (enExample)
MX (1) MXPA03006805A (enExample)
MY (1) MY143685A (enExample)
NO (1) NO332150B1 (enExample)
NZ (1) NZ527863A (enExample)
PL (1) PL211162B1 (enExample)
PT (1) PT1355936E (enExample)
RS (1) RS50857B (enExample)
SG (1) SG149685A1 (enExample)
SI (1) SI1355936T1 (enExample)
SK (1) SK288123B6 (enExample)
TR (1) TR200301208T2 (enExample)
UA (2) UA82983C2 (enExample)
WO (1) WO2002060929A2 (enExample)
ZA (1) ZA200305733B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
JP4259868B2 (ja) * 2001-02-01 2009-04-30 バイオジェン・アイデック・エムエイ・インコーポレイテッド ニューブラスチンのポリマー結合体および同様の使用方法。
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
ES2374971T3 (es) * 2001-03-28 2012-02-23 Biogen Idec Ma Inc. Uso de polipéptidos de neublastina para el tratamiento del dolor neuropático.
PT3025726T (pt) * 2002-01-18 2020-01-09 Biogen Ma Inc Compostos do polímero polialquileno e utilizações dos mesmos
JP4742025B2 (ja) 2003-01-31 2011-08-10 バイオジェン・アイデック・エムエイ・インコーポレイテッド 変異ニューブラスチンのポリマー結合体
EP1897552B1 (en) 2003-04-18 2009-06-17 Biogen Idec MA Inc. Polymer-conjugated glycosylated neublastin
AU2004245175C1 (en) * 2003-06-10 2010-03-18 Biogen Ma Inc. Improved secretion of neublastin
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
CN101043899B (zh) * 2004-08-19 2011-03-30 比奥根艾迪克Ma公司 重折叠转化型生长因子beta家族蛋白
DK1786454T3 (da) * 2004-08-19 2010-09-06 Biogen Idec Inc Neublastinvarianter
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
US20100056440A1 (en) * 2006-03-01 2010-03-04 Biogen Idec Ma Inc. Compositions and methods for administering gdnf ligand family proteins
JP2010503630A (ja) 2006-09-15 2010-02-04 クレアビリス・セラピューティクス・エスピーエー ＨＭＧＢ１のＢｏｘ−ＡおよびＨＭＧＢ１のＢｏｘ−Ａ変異体のポリマー複合体
TWI445544B (zh) 2007-05-01 2014-07-21 Biogen Idec Inc 增進血管形成之組合物及方法
KR20140091721A (ko) * 2011-11-02 2014-07-22 제넨테크, 인크. 오버로드 및 용리 크로마토그래피
RU2488635C1 (ru) * 2012-03-22 2013-07-27 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития Способ получения рекомбинантного антиангиогенного полипептида

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472178B1 (en) * 1998-02-27 2002-10-29 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
WO2000034475A2 (en) * 1998-12-09 2000-06-15 Amgen Inc. Grnf4, a gdnf-related neurotrophic factor
JP4259868B2 (ja) * 2001-02-01 2009-04-30 バイオジェン・アイデック・エムエイ・インコーポレイテッド ニューブラスチンのポリマー結合体および同様の使用方法。

Also Published As

Publication number Publication date
PT1355936E (pt) 2007-09-28
PL211162B1 (pl) 2012-04-30
KR20080098662A (ko) 2008-11-11
SG149685A1 (en) 2009-02-27
NZ527863A (en) 2006-09-29
NO332150B1 (no) 2012-07-09
UA82983C2 (ru) 2008-06-10
JP4259868B2 (ja) 2009-04-30
AR035077A1 (es) 2004-04-14
AU2002247037B2 (en) 2007-08-16
KR100872807B1 (ko) 2008-12-09
EE05537B1 (et) 2012-04-16
CN1500095B (zh) 2010-06-16
GEP20063916B (en) 2006-09-11
DE60220879T2 (de) 2008-03-06
JP4423338B2 (ja) 2010-03-03
KR20030074766A (ko) 2003-09-19
HU228973B1 (en) 2013-07-29
MY143685A (en) 2011-06-30
EP1355936B1 (en) 2007-06-27
NO20033441L (no) 2003-10-01
MXPA03006805A (es) 2003-11-13
SK9712003A3 (en) 2004-01-08
IS6879A (is) 2003-07-17
EP1355936A2 (en) 2003-10-29
UA100967C2 (ru) 2013-02-25
CA2436407C (en) 2011-08-30
HUP0500637A2 (hu) 2005-09-28
CY1106886T1 (el) 2012-09-26
EE200300355A (et) 2003-10-15
ES2289091T3 (es) 2008-02-01
PL372101A1 (en) 2005-07-11
NO20033441D0 (no) 2003-08-01
DK1355936T3 (da) 2007-10-29
RS50857B (sr) 2010-08-31
IL156941A (en) 2008-11-03
BG66393B1 (bg) 2013-11-29
JP2005503763A (ja) 2005-02-10
ZA200305733B (en) 2005-02-23
WO2002060929A3 (en) 2003-03-06
DE60220879D1 (de) 2007-08-09
EP1862475A1 (en) 2007-12-05
JP2009039135A (ja) 2009-02-26
CZ20032080A3 (cs) 2003-10-15
HK1057759A1 (en) 2004-04-16
BR0206852A (pt) 2005-05-03
WO2002060929A2 (en) 2002-08-08
EA009771B1 (ru) 2008-04-28
IS2867B (is) 2014-02-15
CA2436407A1 (en) 2002-08-08
KR100960063B1 (ko) 2010-05-31
BG108111A (bg) 2004-12-30
SI1355936T1 (sl) 2007-12-31
YU61003A (sh) 2006-05-25
EA200300852A1 (ru) 2004-06-24
SK288123B6 (sk) 2013-09-03
HUP0500637A3 (en) 2010-01-28
TR200301208T2 (tr) 2005-05-23
CN1500095A (zh) 2004-05-26
IL156941A0 (en) 2004-02-08

Similar Documents

Publication Publication Date Title
ATE420659T1 (de) Criptoblockierende antikörper und deren verwendung
DE60225204D1 (de) Polymerelektrolyt und Hestellungsverfahren dafür
ATE271066T1 (de) Lösliche mutante ctla4 moleküle und deren verwendung
DE60105859D1 (de) Urazil Verbindungen und deren Verwendung
DE60238894D1 (de) Beleuchtungssystem und dessen Verwendung in Projektionssystem
FI20011421L (fi) Menetelmä ja laite toiminnon toteuttamiseksi
DE60220879D1 (de) Polymer-konjugate von neublastin und methoden für deren verwendung
DE50209372D1 (de) Konjugierte polymere enthaltend spirobifluoren-einheiten und deren verwendung
ATE447561T1 (de) Substituierte aryl 1,4-pyrazin derivate
DE60229819D1 (de) Antriebsstrang und dessen Zusammenbaumethode
HRP20120132A8 (hr) Azabicikloalkani u svojstvu modulatora ccr5
ATE376098T1 (de) Vernetzte pulpe und verfahren zu deren herstellung
DE60237851D1 (de) Modifiziertes Propylenpolymer, dieses enthaltende Zusammensetzung und deren Verwendung
DE60235547D1 (de) En daraus, deren herstellung und verwendung
ATE412013T1 (de) Anti-osteopontin-antikörper und dessen verwendung
DE50111690D1 (de) 2-acyl-indolderivate und deren verwendung als antitumormittel
DE60134126D1 (de) 17-alpha-substituierte-11-beta-substituierte-4-aryl und 21-substituierte 19-norpregnadienedione mit antigestagener aktivität
DE60216345D1 (de) Gummimischung und deren Verwendung
SE9904377D0 (sv) Pharmaceutical combinations
DE50206094D1 (de) Substituierte isoindole und ihre verwendung
DE60201244D1 (de) Polymermodifizierte Gipsmembran und deren Verwendung
DE60024652D1 (de) Unkonjugiertes cyklisches polyencopolymer, kautschukzusammensetzung und verwendung
DE60041418D1 (de) Zusammensetzung für hydrogele, hydrogel und dessen verwendung
DE60230162D1 (de) Polymerisate und ihre verwendung
FI20011370A0 (fi) Biotunnistusmenetelmä ja sitä hyödyntävä laite